乳腺癌化疗呕吐防治药物的应用评价  被引量:2

Evaluation of Drug Use in the Prevention and Treatment of Vomiting for Breast Cancer Patients Treated with Chemotherapy

在线阅读下载全文

作  者:石仁丽 丁选胜[1] 王俐[2] 

机构地区:[1]中国药科大学临床药学教研室,南京210009 [2]南京医科大学附属南京市妇幼保健院,南京210004

出  处:《药学与临床研究》2016年第1期61-65,共5页Pharmaceutical and Clinical Research

摘  要:目的评价乳腺癌化疗患者呕吐防治药使用的合理性.方法:以国际和中国呕吐防治药指南为标准, 评价2014年9月-2015年4月94例乳腺癌化疗患者呕吐防治药应用的合理性,主要分析不同致吐风险级别,化疗的患者应用5-羟色胺3受体拮抗剂(5-HT3RA)及地塞米松等呕吐防治药的合理性.结果:92例(97.9%)患者使用5-HT3RA与指南推荐方案不符,其中63例(67.0%) 帕洛诺司琼的给药频次偏高,80例(85.1%) 重复使用5-HT3RA不合理,31例(33.0%)超致吐风险级别用药;61例(64.9%)使用地塞米松的剂量和疗程低于指南推荐方案.结论:乳腺癌化疗中呕吐防治药应用普遍存在不合理之处.预防化疗所致恶心呕吐,高、中致吐风险级别的患者,在化疗期间应通过增加地塞米松的剂量和疗程来避免过度使用5-HT3RA,低致吐风险级别的患者应单独使用5-HT3RA或地塞米松.通过将用药问题反馈给临床,有助于促进临床合理用药.Objective: To evaluate the rational use of anti-vomiting drugs during the chemotherapy in breast cancer patients. Methods: The use of antiemetic drugs was evaluated on the basis of international and Chinese antiemetic therapy guidelines in 94 patients of breast cancer treated with chemotherapy from September, 2014 to April, 2015. It was mainly analyzed for the rationality of using 5-hydroxytrptamin 3receptor antagonist(5-HT3RA) and dexamethasone, et al in patients under chemotherapy at different emetic risk levels. Results: The 5-HT3 RA using by 92 patients(97.9%) was inconsistent with the guidelines; The use frequency of palonosetron was too high in 63 patients(67%); The repeat use of 5-HT3 RA in 80 patients(85.1%) was unreasonable; 31 patients(33.0%) used antiemetic drugs unnecessarily over their risk levels; 61 patients(64.9%) used dexamethasone under the dose and course recommend by the guidelines.Conclusion: There exists a general phenomenon that the use of antiemetic drugs is not reasonable during chemotherapy in breast cancer patients. There are some advises about preventing nausea and vomiting induced by chemotherapy, patients with high and moderate emetic risk should avoid using 5-HT3 RA excessively by increasing the dose and course of dexamethasone during the chemotherapy, and patients with low emetic risk should use 5-HT3 RA or dexamethasone alone. It can make a significant contribution to the rational use of drugs in clinic through back-feeding the problems of drug application to doctors.

关 键 词:乳腺癌 化疗 呕吐防治药 药物应用评价 合理用药 

分 类 号:R975.4[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象